A prospective multicenter study reports that Woven EndoBridge intrasaccular therapy safely and effectively treats unruptured ...

Ophthalmology is the highest volume outpatient specialty within the NHS and the medicines used for medical retinal vascular conditions account for some of the highest cost and volume treatments used ...

A 65-year-old white woman presented with 9 months of intermittent “kaleidoscopic” visual disturbances and blurred vision upon awakening.Her medical history was significant for hypertension, ...

Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, ...

Recent developments of interest in cardiovascular medicine ...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

The Scientia deal follows Medtronic’s announcement in February that it’ll acquire CathWorks for up to $585 million.

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to ...

The use of sildenafil is associated with an increased risk for serous retinal detachment in men with erectile dysfunction, a ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.

The peripheral vascular device market will rise from $10.4B in 2025 to $14.8B by 2032, driven by drug‑coated balloons, ...

The MHRA has granted marketing authorisation for Eylea® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...